Novel Formulation Development and Evaluation of Transdermal Drug Delivery System

Project Abstract

This project aims to develop and evaluate a novel transdermal drug delivery system (TDDS) that can enhance the therapeutic efficacy and patient compliance of a selected drug. Transdermal drug delivery is a non-invasive route of administration that offers several advantages over conventional oral and parenteral routes, including improved patient compliance, reduced side effects, and the ability to bypass first-pass metabolism. However, the successful development of a TDDS is often hindered by the skin's barrier properties, which limit the permeation of many drug molecules. The focus of this project is to design and optimize a TDDS that can effectively deliver the selected drug through the skin and into the systemic circulation. The project will involve the formulation of different TDDS compositions, including the selection of appropriate excipients, such as permeation enhancers, polymers, and adhesives, to improve the drug's skin permeation and the overall performance of the system. The study will begin with a comprehensive review of the literature to understand the current state of the art in TDDS development, including the challenges and strategies for overcoming the skin's barrier properties. This information will be used to guide the selection of the drug candidate, formulation components, and the overall experimental design. The next phase of the project will involve the development and optimization of the TDDS formulations. This will include the preparation of different TDDS compositions using various techniques, such as solvent casting, hot-melt extrusion, or microemulsion-based methods. The formulations will be thoroughly characterized for their physicochemical properties, including drug content, thickness, tensile strength, and in vitro drug release profile. To assess the skin permeation potential of the developed TDDS, in vitro skin permeation studies will be conducted using relevant skin models, such as excised human or animal skin. The permeation data will be analyzed to determine the rate and extent of drug transport across the skin, as well as the influence of the formulation components on the skin penetration. Furthermore, the project will evaluate the pharmacokinetic and pharmacodynamic performance of the optimized TDDS in appropriate animal models. This will involve the assessment of the drug's systemic absorption, distribution, and therapeutic effects, as well as the safety and tolerability of the formulation. The data generated from the in vitro and in vivo studies will be used to select the most promising TDDS formulation for further development and potential clinical evaluation. The project will also explore the scalability and manufacturing feasibility of the selected TDDS, addressing any challenges related to the industrial-scale production of the system. Overall, this project aims to contribute to the advancement of transdermal drug delivery by developing a novel TDDS that can overcome the skin's barrier and improve the therapeutic outcomes of the selected drug. The successful completion of this project may lead to the development of a new transdermal product that can enhance patient convenience, safety, and treatment efficacy.

Project Overview